Design, synthesis and anti-Alzheimer’s activity of novel 1,2,3-triazole-chromenone carboxamide derivatives
作者:Arezoo Rastegari、Hamid Nadri、Mohammad Mahdavi、Alireza Moradi、Seyedeh Sara Mirfazli、Najmeh Edraki、Farshad Homayouni Moghadam、Bagher Larijani、Tahmineh Akbarzadeh、Mina Saeedi
DOI:10.1016/j.bioorg.2018.10.065
日期:2019.3
trials have failed. Therefore, various factors associated with outset of AD have been considered in targeted drug discovery and development. In this work, a wide range of 1,2,3-triazole-chromenone carboxamides were designed, synthesized, and evaluated for their cholinesterase inhibitory activity. Among them, N-(1-benzylpiperidin-4-yl)-7-((1-(3,4-dimethylbenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-oxo-2H
阿尔茨海默氏病(AD)是一种众所周知的神经退行性疾病,影响着全球数百万的老年人,相应的流行病学数据突显了该疾病的重要性。由于AD是一种多因素疾病,因此已通过临床试验的各种单靶标定向药物都失败了。因此,在靶向药物的发现和开发中已经考虑了与AD发作相关的各种因素。在这项工作中,设计,合成和评估了各种1,2,3-三唑-色酮羧酰胺,并对其胆碱酯酶抑制活性进行了评估。其中,N-(1-苄基哌啶-4-基)-7-((1-(3,4-二甲基苄基)-1H-1,2,3-三唑-4-基)甲氧基)-2-氧代- 2H-chromene-3-carboxamide(11b)表现出最佳的乙酰胆碱酯酶抑制活性(IC50 = 1.80 µM)。它对丁酰胆碱酯酶无活性。应该注意的是,对化合物11b的BACE1抑制活性进行了评估,计算出的IC50 =21.13μM证实了所需的抑制活性。同样,该化合物在50 µM的PC12神经元中表现